Evidence map›Paper›PMID 23013731›Full record

Trial reportInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2012

Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.

Michele L Cote, Govindaraja Atikukke, Julie J Ruterbusch, Sara H Olson, Shawnita Sealy-Jefferson, Benjamin A Rybicki, Sharon Hensley Alford, Mohammad A Elshaikh, Arthur R Gaba, Daniel Schultz and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Michele L CoteBarbara Ann Karmanos Cancer Institute, Detroit, MI, USA. cotem@karmanos.org
Govindaraja Atikukke
Julie J Ruterbusch
Sara H Olson
Shawnita Sealy-Jefferson
Benjamin A Rybicki
Sharon Hensley Alford
Mohammad A Elshaikh
Arthur R Gaba
Daniel Schultz
Ramsi Haddad
Adnan R Munkarah
Rouba Ali-Fehmi
Henry Ford Health System · USWayne State University · USThe Barbara Ann Karmanos Cancer Institute · USMemorial Sloan Kettering Cancer Center · USUniversity of Michigan–Ann Arbor · US

Funding

Exploring Common Linkage Regions in Lung Cancer and COPDK07CA125203 · NCI · WAYNE STATE UNIVERSITY · PI COTE, MICHELE L. · 2008 to 2012
$772k
NCI NIH HHS K07 CA125203
6 · The paper itself

Abstract

objectiveTo describe the pattern and frequency of oncogene mutations in white and African American women with endometrial cancer and to determine if racial differences in oncogene mutations exist among women with pathologically similar tumors.

methodsPatients with endometrial cancer from a large urban hospital were identified through medical records, and representative formalin-fixed paraffin-embedded tumor blocks were retrieved. The study sample included 150 patients (84 African Americans) who underwent total abdominal hysterectomy for endometrial cancer. The Sequenom MassARRAY system and the OncoCarta Assay version 1.0 (Sequenom) were used to test for 238 mutations in 19 common oncogenes. The χ(2) test and the Fisher exact test were used to assess differences in distribution of variables by race and oncogene mutation status.

resultsThere were 20 mutations identified in 2 oncogenes (PIK3CA and KRAS) in tumors from 19 women (12.7%). Most of the mutations were found in PIK3CA (16/20). Thirteen percent of endometrioid tumors harbored mutations (11 PIK3CA and 2 KRAS) as did 29% of the malignant mixed Mullerian tumors (3 PIK3CA and 1 KRAS). There were no observed mutations in serous, clear cell, or mucinous tumor types. Among low-grade endometrioid cancers, tumors from African American patients were significantly associated with harboring either a KRAS or PIK3CA mutation (P = 0.04), with 7 PIK3CA mutations and all 4 KRAS mutations identified in African American women.

conclusionsThis study provides preliminary evidence that oncogene mutation frequency of some subtypes of histologically similar endometrial carcinoma differ by race. Additional studies are needed to further explore this phenomenon in patients with endometrial carcinoma.

Indexed as

Adenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAged, 80 and overBlack or African AmericanClass I Phosphatidylinositol 3-KinasesCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansMiddle AgedMutationNeoplasm GradingNeoplasm StagingClass I Phosphatidylinositol 3-KinasesKRAS protein, humanPhosphatidylinositol 3-KinasesPIK3CA protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID23013731
PMCPMC3512561
OpenAlexW2316638828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.